Hepatitis C virus (HCV) is the most burdensome infectious illness in Canada. Current screening strategies miss a significant proportion of cases, leaving many undiagnosed. Elevated HCV prevalence in those born between 1945 and 1965 has prompted calls for birth-cohort screening in this group. However, Canada lacks population-level data to support this recommendation. We performed a serosurvey to obtain population-based HCV prevalence estimates in Ontario residents born between 1945–1974, to generate evidence for birth-cohort screening recommendations.
We tested anonymized residual sera in five-year age-sex bands from Ontario for anti-HCV antibody. We performed descriptive epidemiological analysis and used a logistic regression model to determine HCV risk-factors.
Of 10,006 sera analyzed, 155 (1.55%, 95% confidence interval (CI) 1.32, 1.81) were positive for HCV antibody. Individuals born between 1950–1964 had a significantly higher combined prevalence of 1.92% (95% CI 1.56, 2.34) compared to 1.14% (95% CI 0.69, 1.77) (p = 0.04) for those born between 1970–1974. For males, comprising 107/155 (69.03%) of positive samples, the highest prevalence was 3.00% (95% CI 1.95, 4.39) for the 1960–1964 birth-cohort. For females, the highest prevalence was 1.56% (95% CI 0.83, 2.65) for those born between 1955–1959. Male sex was significantly associated with positive HCV serostatus.
Citation: Bolotin S, Feld JJ, Garber G, Wong WWL, Guerra FM, Mazzulli T (2018) Population-based estimate of hepatitis C virus prevalence in Ontario, Canada. PLoS ONE 13(1): e0191184. https://doi.org/10.1371/journal.pone.0191184
Editor: Yury E. Khudyakov, Centers for Disease Control and Prevention, UNITED STATES
Received: October 2, 2017; Accepted: December 31, 2017; Published: January 23, 2018
Copyright: © 2018 Bolotin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: Unfortunately, Public Health Ontario (PHO) cannot disclose the underlying data. Doing so would compromise individual privacy contrary to PHO’s ethical and legal obligations. Restricted access to the data may be available under conditions prescribed by the Ontario Personal Health Information Protection Act, 2004, the Ontario Freedom of Information and Protection of Privacy Act, the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS 2 (2014)), and PHO privacy and ethics policies. Data are available for researchers who meet PHO’s criteria for access to confidential data, by filling in a Data Access Request Form, which can be found at http://www.publichealthontario.ca/en/About/Documents/PHO_Data_Request_Form_2017.pdf. Requests should be sent to email@example.com.
Funding: Funding for this study was provided by a Public Health Ontario Project Initiation Fund grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: JJF reports receiving funds for scientific consulting and/or research support from Abbvie, BMS, Gilead, Janssen and Merck. GG has received research support from Gilead, AbbVie, Pfizer, Merck and Janssen. TM is an advisory board member of Roche Diagnostics, Abbott Laboratories, Merck, Paladin, Pfizer, Microbix, bioMerieux, and Qvella. He has received research funding from Qvella, Luminex, and altona diagnostics, and funds for honoraria/scientific consulting from Merck, Abbott, Microbix, and Paladin. WWLW has received research support from the Canadian Liver foundation. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Infection with hepatitis C virus (HCV) is a growing public health concern globally, with 130–150 million chronic cases worldwide and 700,000 deaths annually from HCV-related liver disease . In Canada, HCV is estimated using modeling to chronically infect between 220,697 and 245,987 individuals  and causes the greatest burden of illness of any infectious disease in the country . The majority of those acutely infected are unable to clear the virus, resulting in chronic infection which can progress to cirrhosis and its complications, including hepatocellular carcinoma and liver failure .
HCV testing guidelines have historically been directed at patients in high-risk groups, including persons who inject drugs, incarcerated individuals , symptomatic individuals or those with evidence of chronic liver disease . However, targeted testing often misses a significant proportion of the infected population. Persons in many of the high-risk groups are less likely to access healthcare , and once in care must be recognized by physicians as high-risk to prompt testing. Many infected patients are unaware of their risk factors or choose not to report them because of the stigma associated with high-risk behaviors [8–11]. Symptom-based screening also results in incomplete case finding because most patients have few or no symptoms until liver damage is very advanced . Targeted screening has therefore left a significant proportion of the infected population in Canada undiagnosed. Although precise data are lacking, a recent modeling study suggests that only 56% of HCV-infected individuals in Canada have been diagnosed . The Canadian Health Measures Survey found that only 31% were aware of their infection . However, there are many uncertainties around these figures, partially stemming from poor estimates of national prevalence . Under-diagnosis of HCV is particularly alarming given the rapid progress in development of highly effective well-tolerated antiviral therapy which can cure the infection in upwards of 95% of those treated .
Recent evidence shows that HCV-associated morbidity and mortality is rising [10,14], particularly in the birth cohort born between 1945 and 1965 [9,10,15]. To address this, the Centres for Disease Control and Prevention (CDC) advocated for one-time birth cohort screening for those born between 1945 and 1965, citing evidence that this would identify over 75% of infected individuals and would be cost-effective by preventing downstream complications of HCV infection . Birth cohort screening has also been suggested in Canada, where approximately three-quarters of current cases were born between 1945 and 1975 [8,16]. The cost-effectiveness of this strategy has been demonstrated , and has been recommended by the Canadian Liver Foundation for those born between 1945–1975,  and others . However, recently published guidelines from the Canadian Task Force on Preventative Health Care have recommended against screening asymptomatic adults, including the birth-cohort born between 1945–1975 .
To date, national prevalence estimates for HCV in Canada are based largely on modeling studies, which relied on limited and often poor quality, non-population level data, making it very difficult to develop appropriate policy recommendations. The aim of this study was to perform a serosurvey to obtain a population-based estimate of the prevalence of HCV infection in Ontario by birth cohort, allowing for an estimate of the number of HCV cases by age cohort in Canada.
Materials and methods
Selection of study population
Based on the Canadian Liver Foundation screening recommendations and cost-effectiveness studies, we included residents of Ontario born between 1945 and 1974 [17,18] with a similar number of males and females included in each five-year age-sex band. To account for differences in population densities and possible geographic variability in prevalence across Ontario, the number of sera in the study originating from each of seven public health regions in Ontario varied according to population density in each region, ensuring that our sample was geographically representative of the population of Ontario (Fig 1) .
Sample size calculations
Sample size calculations, performed in Stata 12 (Stata Corporation, College Station, Texas), showed that approximately 10,000 sera, or approximately 833–835 sera per five-year age-sex band, would be required to provide a seroprevalence estimate that would be precise to ±0.2%, ±0.3% and ±0.35% for a prevalence estimate of 1%, 2% and 3%, respectively.
We obtained anonymized residual sera from the largest private diagnostic laboratory in Ontario (LifeLabs, Mississauga, Ontario, Canada). At this laboratory, the most commonly performed tests using sera include electrolytes, lipids and glucose tests. In Ontario, private diagnostic laboratories perform much of the testing for primary care physicians. Through this approach we therefore attempted to target a healthier outpatient population compared to acute or chronically ill populations that are found in hospitals, or samples that required reference testing (including confirmatory testing for HCV), which are commonly submitted to the Public Health Ontario (PHO) Laboratory. Samples in the required strata were collected from August 2014 to February 2015. Following required diagnostic testing, serum samples were de-identified with only information on sex, year-band and Ontario region remaining. Any serum specimen collected from an individual within the birth cohort of interest was eligible for inclusion, provided that it was collected in a serum separator tube, contained a minimum of 2 mL of residual serum and was shipped to PHO within 48 hours of collection.
Samples were shipped to PHO and tested immediately upon arrival. Sera were initially screened for HCV antibody using the Architect Anti-HCV assay (Abbott Diagnostics, Abbott Park, IL, USA). All positive sera were then tested using the Siemens Anti-HCV assay (Siemens Healthcare, Erlangen, Germany) for confirmation.
A univariate analysis of the survey sample, including the proportion from each sex, age-band and region was performed. A bivariate analysis was used to describe these characteristics for HCV antibody positive samples and Wald chi-square tests were used for comparison between groups. Seroprevalence estimates and exact 95% confidence intervals (CI) were calculated for each age-band, sex, age-sex band and region in Ontario. Logistic regression was performed using a forward-building strategy. First, univariate logistic regression was used with HCV antibody positivity as the dependent variable, and sex, age-band and region separately as independent variables. A multivariable logistic regression model was then completed including all independent variables. A test for interaction was performed between age-band and sex.
When comparing prevalence between year-bands of birth, we used the 1970–1974 age-band as a reference, because although this year-band of birth is included in the Canadian Liver Foundation screening recommendation, it is not thought to be part of the birth cohort with elevated HCV prevalence, and jurisidictions such as the US have shown that the prevalence in this group is markedly lower than older cohorts included in our study . To extrapolate estimates to the Canadian population, the age structure was based on 2016 census data  and estimates of HCV prevalence outside of the tested cohort were based on modeling data from Remis et al. .
Risk factors for HCV antibody prevalence
In total, 10,006 sera were included in the analysis (Table 1). Each five-year band comprised between 1666–1669 specimens, representing approximately 16.7% of the total study sample. Overall, 155/10,006 (1.55%, 95% CI 1.32, 1.81) samples were positive for HCV antibody. Seroprevalence estimates varied by year-band of birth (p = 0.08) (Table 2). The oldest and youngest year-bands had the lowest proportions of samples with HCV antibody, with a seroprevalence of 1.02% (95% CI 0.60, 1.63) for samples from individuals born between 1945–1949 and a seroprevalence of 1.14% (95% CI 0.69, 1.77) for samples from individuals born between 1970–1974. Sera from individuals born between 1950–1954 and 1960–1964 had the highest seroprevalence, each at 1.98% (95% CI 1.37, 2.77). Sera from individuals born between 1950–1964 comprised 61.9% of all HCV antibody positive samples, and had a combined prevalence of 1.92% (95% CI 1.56, 2.34). This was significantly higher than the prevalence of our reference group, which was the youngest cohort, born between 1970–1974, which had a prevalence of 1.14% (95% CI 0.69, 1.77) (p = 0.04). Sera from individuals born between 1950–1969 comprised 76.8% of all antibody positive samples, with a combined prevalence of 1.78%, (95% CI 1.48, 2.13). Although the prevalence in this cohort was elevated compared to other age-bands, the difference was not statistically significant when comparing to those born between 1970–1974 (p = 0.07).
Of all HCV antibody positive samples, 107/155 (69.03%) were from males, significantly more than from females (p<0.0001) (Table 2). The overall prevalence of HCV antibody in males was 2.14% (95% CI 1.76, 2.58), and in females was 0.96% (95% CI 0.71, 1.27). For both sexes, HCV antibody prevalence was higher in the middle years of the cohort and lowest for the youngest and oldest year-bands (Fig 2). For males, HCV antibody prevalence by year-band of birth ranged from 1.44% (95% CI 0.74, 2.50) for those born between 1945–1949 to 3.00% (95% CI 1.95, 4.39) for those born between 1960–1964. For females, HCV antibody prevalence by year-band of birth ranged from 0.60% (95% CI 0.20, 1.40) for those born between 1945–1949 and 0.60% (95% CI 0.19, 1.39) for those born between 1970–1974 to 1.56% (95% CI 0.83, 2.65) for those born between 1955–1959.
There were no significant differences in the proportion of positive samples from each Ontario region (p = 0.75) (Table 2). HCV seroprevalence varied from 0.88% (95% CI 0.24, 2.24) in the North East region to 2.20% (95% CI 0.60, 5.53) in the North West region. However, both estimates were derived from small numbers of samples, corresponding to Northern Ontario’s small population, resulting in wide CIs around the point estimates. The seroprevalence in Toronto, the largest city in Ontario, was 1.82% (95% CI 1.28, 2.51).
Using a multivariable logistic regression model adjusted for sex, year-band of birth and region, we found that male sex was significantly associated with positive HCV serostatus (OR 2.26, 95% CI 1.60, 3.19) (Table 3). The highest odds of being HCV seropositive were in individuals born between 1950–1954 and 1960–1964. These age-groups were 1.78 times (95% CI 1.00, 3.14) and 1.77 times (95% CI 1.00, 3.13) more likely to be HCV seropositive compared to those born from 1970–1974, although this association did not reach statistical significance. There was no interaction between sex and year-band of birth.
Population prevalence estimate
If extrapolated to the Canadian population, the measured prevalence in our study would predict that that there are an estimated 227,203 (95% CI 150,316, 330,208) HCV antibody positive individuals in Canada born between the years 1945 to 1974. Using Remis’ estimates for prevalence outside the 1945–1974 cohort , an additional 134,926 individuals are likely to be anti-HCV positive, leading to an overall number of approximately 362,129 infected individuals in Canada. Assuming a spontaneous clearance rate of 26% , our data would suggest that 267,975 individuals have chronic HCV in Canada.
To our knowledge, this is the first study in Canada to assess HCV birth-cohort seroprevalence using residual sera from outpatient laboratory testing. Our analysis reveals an elevated prevalence of HCV antibodies in those born between 1950–1964, with a lower but still elevated prevalence in those born between 1965–1969, compared to those born between 1945–1949 and 1970–1974. This is concordant with studies from other regions, particularly the US, where the 1945–1965 birth cohort was found to account for 76.5% of prevalent HCV infections . The anonymized nature of the testing precludes an exploration of risk factors to explain the higher prevalence in this population. However, based on data from Canada and other regions, it likely reflects past injection drug use as well as iatrogenic transmission through transfusion of blood products or medical procedures abroad or in Canada . Interestingly, we observed a dip in HCV antibody prevalence in samples from males born between 1955–1959 compared to other year-bands in the middle of the cohort. Whether this dip truly represents decreased prevalence in this group or is a statistical aberration is unclear, however, the prevalence in this group was still elevated compared to the oldest and youngest cohorts.
Most estimates of Canadian HCV prevalence to date have been based on modeling from literature using estimates of the numbers in specific risk populations and the estimated prevalence in that population [2,16] or disease reporting data, which represent a mix of incidenct and prevalent cases [15,24]. Using the former approach, in a report for the Public Health Agency of Canada, Remis and colleagues estimated an overall HCV antibody prevalence of 0.78%, rising to just over 1% in older adults . Using similar methods with updated data, Trubnikov estimated an HCV antibody prevalence of 0.96% with a chronic HCV prevalence of 0.71%, assuming a 26% spontaneous clearance rate . Trubnikov also applied the ‘back-calculation’ modeling approach, which estimates prevalence based on outcomes of HCV-related disease and the known natural history of infection, and came to an estimate of chronic HCV prevalence (viremic) of 0.64%. Studies in high-risk populations, using both incidence and diagnostic testing data, have also been performed [25–27]. Although very informative, these estimates are not representative of the general population. Lastly, antibody prevalence measures have been derived from cohort studies of healthy populations, such as first time blood donors  or other study participants. These studies recruit participants from the general population and often exhibit a participation bias towards healthy individuals, and underrepresentation from high-risk populations. Consequently, although these studies each suggested increased HCV prevalence in our birth cohort of interest, the overall prevalence estimates were imprecise and, perhaps not surprisingly, quite low compared to those presented in this study. For example, the Canadian Health Measures Survey  reported an overall HCV seroprevalence of 0.50%, and a seroprevalence of 0.80% for those age 50–79 years.
Although to date, most Canadian HCV prevalence estimates have been lower than those found in our study, our estimates are lower than the estimated 3.25% prevalence in Americans born between 1945–1965 , likely due to differences in the distribution of underlying risk factors and social determinants between the two countries.
There are several limitations to our study. Residual sera submitted for diagnostic testing may reflect a selection bias towards individuals with comorbidities, which may include HCV and could thus overestimate the prevalence in the population. Conversely, our estimates may be falsely low due to the fact that high-risk individuals who make up a substantial proportion of individuals with HCV, such as persons who inject drugs or incarcerated populations, are likely underrepresented as they are less likely to access healthcare services. Since serosurveys use de-identified specimens, we have no information on exposures for participants, limiting our ability to further characterize risk factors for HCV infection in this population. Although large urban centres such as the Greater Toronto Area and Ottawa may contain a higher concentration of high-risk groups, these populations were not specifically over-sampled and as such still likely represent a small proportion of the overall cohort, leading to the likelihood that our estimates are lower than the true seroprevalence in Ontario. We also have no information on what proportion of individuals who tested positive are aware of their infection. Due to the potential for degradation of RNA in samples that were not kept frozen, we were not confident that HCV RNA testing would yield accurate results and thus we were not able to determine the number of HCV cases with chronic infection. However, data in other cohorts suggest that the spontaneous clearance rates in the adult population are approximately 26% , allowing us to make reliable estimates of the prevalence with chronic infection.
Although the geographically representative sample has likely yielded accurate estimates at the provincial level, the number of specimens submitted from Northern Ontario was small, resulting in wide confidence intervals for prevalence estimates in this region. This may be particularly relevant given the higher Aboriginal population in this region, who have a significantly higher prevalence of HCV than the non-Aboriginal Canadian population .
Recently, the Canadian Task Force on Preventative Health Care recommended against birth-cohort screening for HCV due to a lack of high-quality evidence on the effectiveness of screening, high resource implications and financial barriers to accessing treatment . However, the prevalence estimates used in the Task Force recommendations were markedly lower than the ones presented here, and were based on modeling studies rather than population-level seroprevalence data. Our study therefore generates essential data to reframe policy discussions regarding the implementation of population screening strategies for HCV in those born between 1945 and 1974.
This study from a large population-based sample provide robust estimates of HCV prevalence in the population, which are higher than previous estimates from modeling studies, underscoring the value of serosurveys for accurate prevalence data. These results provide updated data to underpin birth cohort screening recommendations for HCV in Canada, in the context of recently available effective direct-acting antiviral drug regimens.
We would like acknowledge the staff at the PHO Laboratory, Mount Sinai Hospital/University Health Network Department of Microbiology and LifeLabs for their assistance with collecting, shipping and testing specimens for this study, as well as Lennon Li for his assistance with statistical analysis.
- 1. World Health Organization (WHO). Hepatitis C Fact sheet. July 2016.
- 2. Trubnikov M, Yan P, Archibald C. Estimated prevalence of Hepatitis C Virus infection in Canada, 2011. CCDR. 2014;40: 429–436.
- 3. Kwong JC, Ratnasingham S, Campitelli MA, Daneman N, Deeks SL, Manuel DG, et al. The impact of infection on population health: results of the Ontario burden of infectious diseases study. PLoS One. 2012;7: e44103. pmid:22962601
- 4. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385: 1124–1135. pmid:25687730
- 5. Ontario Agency for Health Protection and Promotion (Public Health Ontario), Provincial Infectious Diseases Advisory Committee. Recommendations for the public health response to hepatitis C in Ontario. 2014.
- 6. Centers for Disease Control and Prevention (CDC). Testing Recommendations for Hepatitis C Virus Infection. 2015. Available: http://www.cdc.gov/hepatitis/hcv/guidelinesc.htm.
- 7. Grebely J, Raffa J, Lai C, Krajden M, Kerr T, Fischer B, et al. Low uptake of treatment for hepatitis C virus infection in a large community‐based study of inner city residents. J Viral Hepat. 2009;16: 352–358. pmid:19226330
- 8. Shah HA, Heathcote J, Feld JJ. A Canadian screening program for hepatitis C: is now the time? CMAJ. 2013;185: 1325–1328. pmid:24082023
- 9. Smith B, Patel N, Beckett G, Jewett A, Ward W. Hepatitis C virus antibody prevalence, correlates and predictors among persons born from 1945 through 1965, United States, 1999–2008. American Association for the Study of Liver Disease. 2011.
- 10. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep. 2012;61: 1–32.
- 11. Rotermann M, Langlois K, Andonov A, Trubnikov M. Seroprevalence of hepatitis B and C virus infections: Results from the 2007 to 2009 and 2009 to 2011 Canadian Health Measures Survey. Health Reports, Component of Statistics Canada Catalogue no 82-003-X. 2013;24: 3–13.
- 12. Branswell H. Experts say study plays down scale of hepatitis B and C. Globe and Mail. November 21, 2013. Accessed November 21, 2013.
- 13. Canadian Agency for Drugs and Technologies in Health (CADTH). Holkira (Ombitasvir/Paritaprevir/ Ritonavir with Dasabuvir) and Harvoni (Ledipasvir/Sofosbuvir) for Chronic Hepatitis C: A Review of the Clinical Evidence. Rapid Response Report: Summary with Critical Appraisal. 2015.
- 14. Myers RP, Liu M, Shaheen AA. The burden of hepatitis C virus infection is growing: a Canadian population-based study of hospitalizations from 1994 to 2004. Can J Gastroenterol. 2008;22: 381–387. pmid:18414713
- 15. Trubnikov M, Yan P, Njihia J, Archibald C. Identifying and describing a cohort effect in the national database of reported cases of hepatitis C virus infection in Canada (1991–2010): an age-period-cohort analysis. CMAJ Open. 2014;2: E281–7. pmid:25485255
- 16. Remis RS. Modelling the incidence and prevalence of hepatitis C infection and its sequelae in Canada, 2007. PHAC. 2007.
- 17. Wong WW, Tu HA, Feld JJ, Wong T, Krahn M. Cost-effectiveness of screening for hepatitis C in Canada. CMAJ. 2015;187: E110–E121. pmid:25583667
- 18. Canadian Liver Foundation. Position Statement: Hepatitis C Testing. 2012.
- 19. Canadian Task Force on Preventive Health Care. Recommendations on hepatitis C screening for adults. CMAJ. 2017;189: E594–E604. pmid:28438952
- 20. Ontario Ministry of Health and Long-Term Care, IntelliHEALTH Ontario. Population Estimates, 2012. Ontario Ministry of Health and Long-Term Care, IntelliHEALTH Ontario.
- 21. Statistics Canada. Table 051–0001—Estimates of population, by age group and sex for July 1, Canada, provinces and territories, annual (persons unless otherwise noted), CANSIM (database). 2016. Available: http://www5.statcan.gc.ca/cansim/a26?id=510001.
- 22. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13: 34–41. pmid:16364080
- 23. Joy JB, McCloskey RM, Nguyen T, Liang RH, Khudyakov Y, Olmstead A, et al. The spread of hepatitis C virus genotype 1a in North America: a retrospective phylogenetic study. Lancet Infect Dis. 2016;16: 698–702. pmid:27039040
- 24. Public Health Agency of Canada. Hepatitis C in Canada: 2005–2010 Surveillance Report. Centre for Communicable Diseases and Infection Control, Infectious Disease Prevention and Control Branch, Public Health Agency of Canada. 2011.
- 25. Wood E, Kerr T, Stoltz J, Qui Z, Zhang R, Montaner JS, et al. Prevalence and correlates of hepatitis C infection among users of North America's first medically supervised safer injection facility. Public Health. 2005;119: 1111–1115. pmid:16214189
- 26. Stewart LA, Nolan A, Sapers J, Power J, Panaro L, Smith J. Chronic health conditions reported by male inmates newly admitted to Canadian federal penitentiaries. CMAJ Open. 2015;3: E97–E102. pmid:25844377
- 27. Buxton JA, Yu A, Kim PH, Spinelli JJ, Kuo M, Alvarez M, et al. HCV co-infection in HIV positive population in British Columbia, Canada. BMC Public Health. 2010;10: 225. pmid:20429917
- 28. O'Brien SF, Fan W, Xi G, Yi QL, Goldman M, Fearon MA, et al. Declining hepatitis C rates in first-time blood donors: insight from surveillance and case-control risk factor studies. Transfusion. 2008;48: 902–909. pmid:18208409
- 29. Minuk GY, Uhanova J. Viral hepatitis in the Canadian Inuit and First Nations populations. Can J Gastroenterol. 2003;17: 707–712. pmid:14679425